clipped from www.prnewswire.com Late-stage IDENTITY study of once-daily, oral agent is now enrolling Eli Lilly and Company Slowing the rate of disease progression could preserve independent LY450139 is being tested IDENTITY is a randomized, double-blind, placebo-controlled trial that information regarding the IDENTITY trial, including global |
I became a CareGiver by choice. I cared for my mother for many years. Caregiver is a companion site of the Alzheimer's Reading Room.